Haleon reports slower 1Q organic revenue growth due to weaker cold/flu season and China demand, anticipates 4%-6% organic growth in 2024.

Haleon, the consumer healthcare company spun off from GSK, reported slower first-quarter organic revenue growth due to a weaker cold and flu season and reduced demand in China. Despite price increases, generic competition remains a challenge. The company anticipates overall revenue growth of just below 4% in the first quarter of 2023 and organic revenue to rise 4%-6% in 2024, with adjusted operating profit ahead of this range.

February 29, 2024
18 Articles

Further Reading